A treat-to-target approach is gaining ground as an effective and efficient strategy for a range of rheumatic diseases (1-4). It is assumed that a treatment continuously aimed at a single target-abrogation of inflammation, leading to remission-will have "domino effects" on all other treatment goals as well (1). Since the first recommendations were published there have been new insights, and there is a need to revisit the discussion. In this commentary we will reflect on treat-to-target in rheumatic diseases from the patient perspective, based on our experiences as patient representatives in research on rheumatoid arthritis (RA), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA).